

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Richard Franklin

Application No.: 10/762,566

Confirmation No.: 3220

Filed: January 23, 2004

Art Unit: 1614

For: FORMULATION AND METHODS FOR THE  
TREATMENT OF THROMBOCYTHEMIA

Examiner: A. R. Hughes

**AMENDMENT AFTER FINAL ACTION UNDER 37 C.F.R. 1.116**

MS AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INTRODUCTORY COMMENTS**

In response to the Office Action dated January 28, 2008, please amend the above-identified U.S. patent application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 3 of this paper.

**Remarks/Arguments** begin on page 8 of this paper.

This Amendment is accompanied by Exhibit 1 (the Citizen Petition dated August 13, 2004 related to anagrelide), Exhibit 2 (Wagstaff and Keating, *Drugs* 2006, 66:111-131), and Exhibit 3 (Wang *et al.*, *British Journal of Pharmacology* 2005, 146:324-332), an Information Disclosure Statement listing Exhibits 1-3, and a Request for Continued Examination (RCE) and associated fee.

It is believed that no additional fee is required for this Amendment. However, should an additional fee be necessary in connection with the filing of this Response, or if a petition for extension of time is required for timely acceptance of the same, the Commissioner is hereby authorized and requested to charge Deposit Account No. 04-0100 for any such fees, and Applicant hereby petition for any needed extension of time.